Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Faron Pharmaceuticals Oy ( (GB:FARN) ) has issued an announcement.
Faron Pharmaceuticals announced that its Non-Executive Chairman, Tuomo Pätsi, acquired 21,500 ordinary shares in the company, increasing his total holdings to 53,265 shares, which represents 0.05% of the voting rights. This transaction reflects potential confidence in the company’s future, possibly impacting investor perception and stakeholder interests.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing novel immunotherapies to tackle cancers. The company’s lead asset is bexmarilimab, an investigational immunotherapy designed to overcome resistance to existing treatments by targeting myeloid cell function and reprogramming the immune system.
See more insights into FARN stock on TipRanks’ Stock Analysis page.